Keyphrases
Alzheimer's Disease
73%
Dominantly Inherited Alzheimer's Disease
68%
Clinical Trials
55%
Autosomal Dominant Alzheimer's Disease
51%
Dominantly Inherited Alzheimer Network
38%
Symptom Onset
33%
Gantenerumab
29%
Rate of Change
28%
Mutation Carriers
27%
Solanezumab
22%
Disease Progression
22%
Sporadic Alzheimer's Disease
22%
Non-carriers
19%
Alzheimer's Disease Clinical Trials
18%
Longitudinal Change
18%
Clinical Outcomes
18%
Cerebrospinal Fluid
18%
Standardized Uptake Value
16%
Multiple Sclerosis
15%
Pittsburgh Compound B
14%
Treatment Effect
14%
Mixed Model Repeated Measures
13%
Prevention Trials
13%
DIAN-TU
12%
Dementia
12%
Linear Mixed Model
12%
Placebo
12%
Mini-Mental State Examination
11%
Total tau
11%
Biomarker Changes
11%
Cognitive Decline
11%
Amyloid Burden
11%
Alzheimer's Disease Prevention
11%
Mild Cognitive Impairment
10%
Longitudinal Data
10%
Positron Emission Tomography
10%
Neurodegeneration
10%
Early Alzheimer's Disease
10%
Disease Progression Modeling
10%
Practice Effects
10%
Sample Size Re-estimation
10%
Cognitive Impairment
10%
Decline Rate
9%
Progression Rate
9%
Disease Stage
9%
Alzheimer's Disease Biomarkers
9%
Disease Course
8%
Cognitive Outcome
8%
Biomarker Profile
8%
Clinical Dementia Rating
8%
Medicine and Dentistry
Alzheimer's Disease
100%
Amyloid
43%
Biological Marker
33%
Gantenerumab
29%
Clinical Trial
28%
Symptom
25%
Positron Emission Tomography
22%
Solanezumab
22%
Autosomal Dominant Inheritance
21%
Cerebrospinal Fluid
18%
Tau
18%
Disease
13%
Placebo
12%
Multiple Sclerosis
10%
Radioactive Tracer
10%
Pittsburgh Compound B
10%
Standardized Uptake Value
10%
Disease Exacerbation
9%
Neurodegeneration
7%
Neuroinflammation
7%
Amyloid Plaque
7%
Positron Emission Tomography
7%
Clinical Dementia Rating
5%
Prophylaxis
5%
Carbon 11
5%
Amyloidosis
5%
Alzheimer's Disease Clinical Trial
5%
Treatment Effect
5%
Observational Study
5%
Tumor Marker
5%
Cross Sectional Study
5%
Early-Onset Alzheimer's Disease
5%
Cerebral Atrophy
5%
Subgroup Analysis
5%
Patient with Alzheimer's Disease
5%
Triple Negative Breast Cancer
5%
Latent Class Analysis
5%
Down Syndrome
5%
Randomized Clinical Trial
5%
Health Behavior
5%
Electroencephalography Monitoring
5%
Signaling Mechanism
5%
Glasgow Coma Scale
5%
Monoclonal Antibody
5%
Presenilin 1
5%
Florbetapir (18F)
5%
Intensive Care Unit
5%
Attitude
5%
Alzheimer Disease Assessment Scale
5%
Small Vessel Disease
5%